Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

• Published in: Influenza and other respiratory viruses 2024-04, Vol.18 (4), p.e13292-n/a
• Main Authors: Monge, Susana, Humphreys, James, Nicolay, Nathalie, Braeye, Toon, Van Evercooren, Izaak, Holm Hansen, Christian, Emborg, Hanne‐Dorthe, Sacco, Chiara, Mateo‐Urdiales, Alberto, Castilla, Jesús, Martínez‐Baz, Iván, Gier, Brechje, Hahné, Susan, Meijerink, Hinta, Kristoffersen, Anja Bråthen, Machado, Ausenda, Soares, Patricia, Nardone, Anthony, Bacci, Sabrina, Kissling, Esther, Nunes, Baltazar
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; cohort design; COVID-19; COVID-19 - epidemiology; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Effectiveness; Electronic Health Records; Estimates; Europe - epidemiology; European Union; Female; hospitalisation; Hospitalization; Hospitalization - statistics & numerical data; Humans; Infections; Male; Mortality; multicountry study; Older people; Patient admissions; Retrospective Studies; SARS-CoV-2 - immunology; SARS‐CoV‐2; Severe acute respiratory syndrome coronavirus 2; Short Communication; Short Communications; Vaccination - statistics & numerical data; vaccine effectiveness; Vaccine Efficacy; Vaccines
• ISSN: 1750-2640; 1750-2659
• DOI: 10.1111/irv.13292

ABSTRACT Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID‐19 hospitalisation and death in booster‐eligible ≥ 65‐year‐olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID‐19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65‐ to 79‐year‐olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80‐year‐olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.